A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab
(CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.